Neofect Unveils Robotics Dual-Track Plan... Second-Generation Healthcare Robot to Debut at CES 2027

Neofect, a specialist in artificial intelligence (AI) healthcare robotics, has declared its ambition to become a global healthcare robot company.

On the 5th, Neofect announced that it will unveil a mid- to long-term "Robotics Dual-Track" strategic roadmap. The company plans to lead the global medical robotics market by advancing its existing technologies and expanding into new markets.

The key elements are: ▲ upgrading its current flagship product, the "Smart Glove," into an advanced rehabilitation device that integrates AI and robotics technologies ▲ expanding the wearable robotic hand assist device "Neomano" into everyday-life and industrial robotics applications ▲ establishing a technology roadmap that encompasses brain-computer interface (BCI), a next-generation technology, and lower-limb rehabilitation robots.

More specifically, the "Smart Glove" will evolve from the existing sensor-based measurement method into a "second-generation hybrid rehabilitation robot" powered by AI. An exoskeleton structure, continuous passive motion (CPM) hardware, and AI control algorithms will be combined so that the system can analyze the patient's finger spasticity and movement intent in real time, and automatically adjust personalized active assistance and timing. The company is accelerating development with the goal of unveiling the product at the Consumer Electronics Show (CES) in January 2027.

The other key pillar, "Neomano," will leverage its patents for medical, rehabilitation, and therapeutic use, its U.S. Food and Drug Administration (FDA)-approved technologies, and its commercialization track record to enter the everyday-life and industrial wearable robot market for workers in precision assembly industries such as semiconductors and displays, where fingers are used repeatedly. Neofect plans to optimize the existing product's powerful wire-driven technology and durability for the work environment, and expand its use as a smart assistive solution that reduces work fatigue and prevents musculoskeletal disorders. Since the current product is already used as a medical device for people with spinal cord injuries, the company believes that applying the existing technology will give it broad versatility in both daily life and industrial settings.

Neofect also presented its plans for commercializing BCI technology. The company is currently working with Seoul National University Bundang Hospital and Germany's Charite University Hospital to develop a "non-invasive BCI-based upper-limb rehabilitation robot system." The system analyzes brain waves and decodes the user's intention to move the hand simply by wearing a headset, without implanting any chips, and then operates the robot accordingly. Ultimately, the goal is to complete an "ultra-connected Neuralink robotics" system that allows users to control rehabilitation equipment using only their thoughts.

Meanwhile, Neofect has signaled that it will expand its business domain from upper-limb rehabilitation to the lower-limb segment. Based on the precise joint control algorithms and commercialization know-how it has accumulated through the Smart Glove and Smart Board, the company aims to develop high-performance lower-limb rehabilitation robots capable of competing with Japan's Cyberdyne and the United States' Ekso Bionics. Neofect plans to maximize efficiency by applying its proven user-intent recognition technology from upper-limb rehabilitation to gait assistance, and to complete a next-generation product lineup with a lightweight solution that addresses the weight and bulk issues that have been cited as weaknesses of existing lower-limb robots.

A Neofect representative said, "The core of this roadmap is to evolve the Smart Glove into a state-of-the-art medical robot that integrates AI and BCI, and to develop Neomano into a wearable robot that can be used in everyday life and industrial settings," adding, "Neofect will grow into a company that leads the global medical AI and healthcare robotics market."